Updated Investor Presentation: H1FY27 RoE revised to 6.3%, Debt to EBITDA to 1.16
Tatva Chintan has shared a revised Q2/H1 FY27 investor presentation, correcting typographical errors on page 12.
By ScoutQuest · · 2 min read
- Revised H1FY27 RoE
- 6.3% (earlier 2.6%)
- Revised Debt to EBITDA
- 1.16, an annualised figure (earlier 4.30)
- Period covered
- Q2/H1 FY27, quarter and half year ended 30 September 2026
What the update says
Tatva Chintan Pharma Chem Limited has submitted an updated investor presentation for the quarter and half year ended 30 September 2026. The company said typographical errors were noticed on page 12 of the presentation circulated earlier the same day, and it has enclosed the corrected details together with the earlier details.
What was revised
- Return on Equity (RoE) for H1FY27: updated to 6.3%, earlier shown as 2.6%
- Debt to EBITDA: updated to 1.16, earlier shown as 4.30
- The updated Debt to EBITDA is marked as an annualised figure.
The company also stated that there are no changes in the other financial numbers reported in the presentation for the quarter and half year ended 30 September 2026. It said it regrets the typographical errors and has taken steps to prevent their recurrence.
Why these two ratios are watched
- RoE shows how much profit a company earns on shareholders' funds. A higher reading means more profit for every rupee of equity.
- Debt to EBITDA compares borrowings with operating profit. A lower multiple means less debt relative to earnings.
Both of the revised figures differ from the earlier printed ones, so the corrected page presents a different picture of profitability on equity and of leverage than the first version.
What the presentation says about the quarter
The Chairman and Managing Director's message describes the quarter under review as a landmark one, with the company achieving its highest-ever quarterly turnover. It adds that the established SDA business continues to provide strong momentum, while newer initiatives in energy storage and agro and pharma intermediates are progressively opening up additional opportunities and are on a path of consistent growth.
What a retail investor may note
- The revision is confined to the two ratios; the remaining numbers in the presentation are stated to be unchanged.
- Both revised figures relate to H1FY27, the half year ended 30 September 2026.
- The corrected version replaces the earlier presentation, and the company has placed the information on its website.
Also from Tatva Chintan Pharma Chem
Tatva Chintan Pharma shares fell about 10% to their lowest level in 23 sessions
22 Oct 2026
Tatva Chintan Pharma rose on good numbers and is holding up even in a weak market; a guest said the trend is positive and gave a hold call
21 Oct 2026
Tatva Chintan Q2FY27 revenue up 76% YoY to ₹2,173 Mn, PAT up 116%
19 Oct 2026
More numbers
- RoE H1FY27 (updated)6.3%
- RoE H1FY27 (earlier)2.6%
- Debt to EBITDA H1FY27 (updated, annualised)1.16*
- Debt to EBITDA H1FY27 (earlier)4.30
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.